The Furiex Management Team
Furiex has assembled a world-class team of drug development experts, bringing extensive experience across a wide range of therapeutic areas. Our leadership team collectively has more than 75 years of experience. Together, we build value by designing innovative programs that drive development faster and more efficiently across the development timeline.
Management TeamTOP
-
June Almenoff, M.D., Ph.D., FACP
President and Chief Medical Officer
June Almenoff, M.D., Ph.D., is president and chief medical officer, and serves on the board of directors. She is Furiex's principal executive officer. Dr. Almenoff joined Furiex after a successful 12-year career at GlaxoSmithKline, and has served as president and chief medical officer of Furiex since its inception in 2010.
More -
Chief Financial Officer, Treasurer and Assistant Secretary
Mr. Marshall Woodworth has 14 years of experience in the biopharmaceutical industry, including various positions at Eli Lilly and Company. At Furiex, he is responsible for finance, accounting, human resources and purchasing.
More -
Senior Vice President, Clinical Development and Operations
Dr. Paul Covington brings more than 17 years of drug development experience overseeing all aspects of medical and regulatory affairs including pharmacovigilance, medical writing and program management. Dr. Covington also has experience as a medical practitioner in both hospital and private practice settings.
More -
Gail McIntyre, Ph.D., CH (ASCP), DABT
Senior Vice President, Research
Dr. Gail McIntyre has more than 19 years of experience in the drug discovery and development industry at both biotechnology and pharmaceutical companies. She is a board certified toxicologist with extensive experience in moving compounds through the lead optimization phase to IND. Dr. McIntyre led PPD's compound partnering group for six years.
More -
Vice President, Legal Affairs and Secretary
Dr. Nadine Chien has more than 11 years of experience in intellectual property, licensing and other transactional work. She has extensive experience negotiating and managing strategic alliances. Her areas of scientific expertise include molecular and cellular biology, genomics and biochemistry.
More -
Vice President, Strategic Development
Mr. Sailash Patel has more than 10 years of experience in the pharmaceutical industry. His wide-ranging business experience includes corporate strategic planning, mergers and acquisitions, and therapeutic strategic alliance business development. Mr. Patel has supported transactions with an aggregate value in excess of $800 million.
More